Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis May 10, 2021
Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet May 10, 2021
Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference Apr 15, 2021
Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings Apr 8, 2021
Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report Mar 15, 2021
Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights Feb 24, 2021
